SEARCH

SEARCH BY CITATION

References

  • 1
    Hoitsma AJ, Hilbrands LB. Relative risk of new-onset diabetes during the first year after renal transplantation in patients receiving tacrolimusrolimus or cyclosporine immunosuppression. Clin Transplant 2006; 20: 659664.
  • 2
    David E, Lemos FC, Fadel LM, Agena F, Sato MY, Coccuza C et al. The dynamics of glucose metabolism under calcineurin inhibitors in the first year after renal transplantation in nonobese patients. Transplantation 2007; 84: 5055.
  • 3
    Cosio FG, Kudva Y, van der Velde M, Larson TS, Textor SC, Griffin MD et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67: 24152421.
  • 4
    Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178185.
  • 5
    Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimusrolimus. Am J Transplant 2007; 7: 15061514.
  • 6
    Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004; 4: 583595.
  • 7
    Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002; 25: 583592.
  • 8
    Mak RH. Insulin and its role in chronic kidney disease. Pediatr Nephrol 2008; 23: 355362.
  • 9
    Kutkuhn B, Hollenbeck M, Heering P, Koch M, Voiculescu A, Reinhard T et al. Development of insulin resistance and elevated blood pressure during therapy with cyclosporine A. Blood Press 1997; 6: 1317.
  • 10
    Duijnhoven EM, Boots JM, Christiaans MH, Wolffenbuttel BH, Van Hooff JP. Influence of tacrolimusrolimus on glucose metabolism before and after renal transplantation: a prospective study. J Am Soc Nephrol 2001; 12: 583588.
  • 11
    Hjelmesaeth J, Hagen LT, Asberg A, Midtvedt K, Storset O, Halvorsen CE et al. The impact of short-term cyclosporine A treatment on insulin secretion and insulin sensitivity in man. Nephrol Dial Transplant 2007; 22: 17431749.
  • 12
    Undre NA, van Hooff J, Christiaans M, Vanrenterghem Y, Donck J, Heeman U et al. Low systemic exposure to tacrolimusrolimus correlates with acute rejection. Transplant Proc 1999; 31: 296298.
  • 13
    Mahalati K, Belitsky P, West K, Kiberd B, Fraser A, Sketris I et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol 2001; 12: 828833.
  • 14
    Karamperis N, Povlsen JV, Hojskov C, Poulsen JH, Pedersen AR, Jorgensen KA. Comparison of the pharmacokinetics of tacrolimusrolimus and cyclosporine at equivalent molecular doses. Transplant Proc 2003; 35: 13141318.
  • 15
    Porksen N, Munn S, Steers J, Vore S, Veldhuis J, Butler P. Pulsatile insulin secretion accounts for 70% of total insulin secretion during fasting. Am J Physiol 1995; 269: E478E488.
  • 16
    Juhl CB, Hollingdal M, Porksen N, Prange A, Lonnqvist F, Schmitz O. Influence of rosiglitazone treatment on beta-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatility. J Clin Endocrinol Metab 2003; 88: 37943800.
  • 17
    Ferrannini E. The theoretical bases of indirect calorimetry: a review. Metabolism 1988; 37: 287301.
  • 18
    Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 1983; 55: 628634.
  • 19
    Ozbay LA, Moller N, Juhl C, Bjerre M, Carstens J, Rungby J et al. Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers. Br J Clin Pharmacol 2012; 73: 536545.
  • 20
    DeFronzo RA, Tobin JD, Rowe JW, Andres R. Glucose intolerance in uremia. Quantification of pancreatic beta-cell sensitivity to glucose and tissue sensitivity to insulin. J Clin Invest 1978; 62: 425435.
  • 21
    Ferrannini E, Mari A. How to measure insulin sensitivity. J Hypertens 1998; 16: 895906.
  • 22
    Carrero JJ, Cordeiro AC, Lindholm B, Stenvinkel P. The emerging pleiotrophic role of adipokines in the uremic phenotype. Curr Opin Nephrol Hypertens 2010; 19: 3742.
  • 23
    Fernandez LA, Lehmann R, Luzi L, Battezzati A, Angelico MC, Ricordi C et al. The effects of maintenance doses of FK506 versus cyclosporine A on glucose and lipid metabolism after orthotopic liver transplantation. Transplantation 1999; 68: 15321541.
  • 24
    Lafuente A, Alvarez-Demanuel E, Blanco A, Garcia-Bonacho M, Esquifino AI. Effects of cyclosporine on circulating levels of prolactin, LH, FSH, TSH and GH in chronic hyperprolactinemic male rats. Rev Esp Fisiol 1996; 52: 161166.
  • 25
    Valera Mora ME, Scarfone A, Calvani M, Greco AV, Mingrone G. Insulin clearance in obesity. J Am Coll Nutr 2003; 22: 487493.
  • 26
    Strumph P, Kirsch D, Gooding W, Carroll P. The effect of FK506 on glycemic response as assessed by the hyperglycemic clamp technique. Transplantation 1995; 60: 147151.
  • 27
    Robertson RP, Franklin G, Nelson L. Intravenous glucose tolerance and pancreatic islet beta-cell function in patients with multiple sclerosis during 2-year treatment with cyclosporin. Diabetes 1989; 38: 5864.
  • 28
    Konrad T, Steinmuller T, Vicini P, Toffolo G, Grewerus D, Schuller A et al. Regulation of glucose tolerance in patients after liver transplantation: impact of cyclosporin versus tacrolimusrolimus therapy. Transplantation 2000; 69: 20722078.
  • 29
    Rickels MR, Mueller R, Teff KL, Naji A. Beta-cell secretory capacity and demand in recipients of islet, pancreas, and kidney transplants. J Clin Endocrinol Metab 2010; 95: 12381246.